06.03.2020 | Original Article
Diagnosis of bladder cancer using 18F-labeled α-methyl-phenylalanine tracers in a mouse model
Erschienen in: Annals of Nuclear Medicine | Ausgabe 5/2020
Einloggen, um Zugang zu erhaltenAbstract
Objective
Although 2-18F-fluoro-2-deoxy-glucose (18F-FDG) has established roles in the diagnosis of a variety of cancers, it has limited value in the detection of primary/recurrent lesions in the bladder, mainly because of interference by the pooled radioactivity in the urine. Our previous study revealed promising properties of l- and d-2-18F-α-methyl-phenylalanine (2-18F-FAMP) as radiotracers; i.e., their rapid blood clearance and low renal accumulation. In the present study we evaluated the utility of l- and d-2-18F-FAMP for imaging bladder cancer in a mouse model.
Methods
We used the human bladder cancer cell line HT1376 to prepare a bladder cancer xenograft model in mice bearing both orthotopic and subcutaneous tumors. Biodistribution and PET imaging studies were performed at 1 and 3 h after injection of l-2-18F-FAMP or d-2-18F-FAMP. 18F-FDG was used as a control.
Results
At 1 h after injection, greater accumulations of both l-2-18F-FAMP and d-2-18F-FAMP were observed in the orthotopic tumors compared to 18F-FDG. The orthotopic tumor-to-muscle ratio of d-2-18F-FAMP was significantly higher than that of 18F-FDG (p < 0.01), because of the rapid blood clearance of d-2-18F-FAMP. l-2-18F-FAMP showed the highest subcutaneous tumor-to-muscle ratio (p < 0.01) due to its high subcutaneous tumor uptake. Compared to l-2-18F-FAMP, d-2-18F-FAMP exhibited faster clearance and lower kidney accumulation. In the PET imaging studies, l- and d-2-18F-FAMP both clearly visualized the orthotopic bladder tumors at 1 h after injection.
Conclusion
Our study showed that l-2-18F-FAMP and d-2-18F-FAMP have the potential to detect bladder cancer.
Anzeige